Hepatoprotective effects of Yinchenzhufu decoction on intrahepatic cholestasis liver injury in mice induced by ANIT via suppressing TLR4/NF-κB pathway

doi:10.12092/j.issn.1009-2501.2020.06.001

Abstract

Abstract: AIM: To investigate the hepatoprotective effects of Yinchenzhufu decoction (YCZFD) via TLR4/NF-κB pathway on the hepatic injury in alpha-naphthyisothiocyanate (ANIT)-induced intrahepatic cholestasis mice. METHODS: Male C57BL/6 mice were administered with YCZFD for consecutive 10 days, and intrahepatic cholestasis mice model was induced by orally given ANIT at dose of 75 g/kg on the seventh day. On the last day, the blood samples and liver samples were collected 2 hours after oral administration of YCZFD. The serum biochemical index, liver histopathology, the change of bile acid contents in mice liver, and the expression of relative proteins in TLR4/NF-κB pathway were determined. RESULTS: Compared with the model group, YCZFD treatment group significantly improved the hepatic necrosis and reduced the inflammatory cell infiltration. The plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bile acid (TBA), and total bilirubin (TBIL) levels were significantly decreased, and the free and conjugated bile acids were both reduced. The expression of TLR4, IL-1β, IL-6, TNF-α, and MCP-1 were significantly decreased. CONCLUSION: YCZFD presents hepatoprotective effects on the hepatic injury in ANIT-induced intrahepatic cholestasis mice, which may be related to inhibiting the TLR4/NF-κB pathway, reducing the intrahepatic bile acids, and suppressing the inflammatory reaction.

Key words: cholestasis liver injury, TLR4/NF-κB pathway, Yinchenzhufu decoction

CLC Number:

R965.2

WANG Qian, SU Huizong, LI Yue, TAN Bo, YAN Dongming, JIN Jingyi, QIU Furong. Hepatoprotective effects of Yinchenzhufu decoction on intrahepatic cholestasis liver injury in mice induced by ANIT via suppressing TLR4/NF-κB pathway[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 601-609.

References 24

[1]	胆汁淤积性肝病诊断治疗专家共识2015年更新专家委员会.胆汁淤积性肝病诊断治疗专家共识:2015年更新 [J].临床肝胆病杂志, 2015,31(10): 1563-1574.
[2]	De Vries E, Beuers U. Management of cholestatic disease in 2017 [J]. Liver Int, 2017, 37(Suppl1): 123-129.
[3]	黄建荣. 肝内胆汁淤积症诊治专家共识解读 [J]. 中国医学前沿杂志(电子版), 2016, 8(3): 9-11.
[4]	Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver [J]. Mol Aspects Med, 2017, 56(8): 45-53.
[5]	张林林, 樊玉娟, 谭波, 等. 熊脱氧胆酸在慢性肝病中应用及机制的再认识 [J]. 中国临床药理学与治疗学, 2017, 22(2): 233-240.
[6]	Zhang L, Su H, Li Y, et al. Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice [J]. Toxicol App Pharmacol, 2018, 342(3): 69-78.
[7]	王晓丽, 黄古叶, 赵凯杰, 等. 经方治疗黄疸临床研究进展 [J]. 中医药临床杂志, 2019, 31(4): 792-795.
[8]	Ma D, Zhang J, Zhang Y, et al. Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice [J]. Int Immunopharmacol, 2018, 55(2): 237-244.
[9]	Gu XJ, Xu J, Ma BY, et al. Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism [J]. Chin J Traumatol, 2014, 17(1): 1-7.
[10]	周兴华, 钟振东, 钟森, 等. 加味茵陈蒿汤对肝损伤大鼠TLR4 mRNA及其蛋白表达的影响 [J]. 中国实验方剂学杂志, 2013, 19(15): 239-242.
[11]	Desmet VJ, Krstulovic B, Van Damme B. Histochemical study of rat liver in alpha-naphthyl isothiocyanate (ANIT) induced cholestasis [J]. Am J Pathol, 1968, 52(2): 401-421.
[12]	Osterreicher CH, Trauner M. Xenobiotic-induced liver injury and fibrosis [J]. Expert Opin Drug Metab Toxicol, 2012, 8(5): 571-580.
[13]	Rudich N, Zamir G, Pappo O, et al. Focal liver necrosis appears early after partial hepatectomy and is dependent on T cells and antigen delivery from the gut [J]. Liver Int, 2009, 29(8): 1273-1284.
[14]	沈淑娇, 张志荣, 曾金, 等. LC-MS/MS测定小鼠肝脏中10种胆汁酸浓度的方法与应用 [J]. 肝脏, 2015, 20(4): 285-290, 294.
[15]	Carpenter-Deyo L, Marchand DH, Jean PA, et al. Involvement of glutathione in 1-naphthylisothiocyanate (ANIT) metabolism and toxicity to isolated hepatocytes [J]. Biochem Pharmacol, 1991, 42(11): 2171-2180.
[16]	张丹, 马岚青. 过氧化物酶体增殖激活受体α在肝脏疾病中的作用及机制 [J]. 临床肝胆病杂志, 2019, 35(10): 2351-2354.
[17]	Cai SY, Ouyang X, Chen Y, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response [J]. JCI Insight, 2017, 2(5): e90780.1-13.
[18]	Cai SY, Boyer JL. Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury [J]. Inflamm Cell Signal, 2017, 4(2): 1-6.
[19]	Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease [J]. Nat Rev Immunol, 2017, 17(5): 306-321.
[20]	Cai SY, Boyer JL. The role of inflammation in the mechanisms of bile acid-induced liver damage [J]. Dig Dis, 2017, 35(3): 232-234.
[21]	张志荣, 张林林, 樊玉娟, 等. 茵甘合剂对ANIT诱导肝内胆汁淤积模型小鼠肝损伤防治作用及机制研究 [J]. 肝脏, 2017, 22(2): 119-124.
[22]	Wang Q, Jiang P, Ye FY, et al. Identification and pharmacokinetics of multiple constituents in rat plasma after oral administration of Yinchenzhufu Decoction [J]. J Ethnopharmacol, 2014, 153(3): 714-724.
[23]	Yang G, Zhang L, Ma L, et al. Glycyrrhetinic acid prevents acetaminophen- induced acute liver injury via the inhibition of CYP2E1 expression and HMGB1-TLR4 signal activation in mice [J]. Int Immunopharmacol, 2017, 50: 186-193.
[24]	Shi H, Dong L, Jiang J, et al. Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway [J]. Toxicology, 2013, 303(1): 107-114.